Intravitreal Bevacizumab for Diabetic Macular Edema
Primary Purpose
Macular Edema, Diabetic Retinopathy
Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Bevacizumab
Sponsored by
About this trial
This is an interventional trial for Macular Edema
Eligibility Criteria
Inclusion Criteria:
- Diabetes mellitus
- Clinically significant macular edema
- Possibility of performing macular OCT
- Consent of patient for inclusion in the study
Exclusion Criteria:
- History of macular photocoagulation in less than 6 months of inclusion in the study
- Necessity of surgical intervention
- Rejection of the remaining in the study by patient
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00703235
First Posted
June 20, 2008
Last Updated
June 20, 2008
Sponsor
Isfahan Ophthalmology Research Center
1. Study Identification
Unique Protocol Identification Number
NCT00703235
Brief Title
Intravitreal Bevacizumab for Diabetic Macular Edema
Study Type
Interventional
2. Study Status
Record Verification Date
June 2008
Overall Recruitment Status
Unknown status
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Isfahan Ophthalmology Research Center
4. Oversight
5. Study Description
Brief Summary
Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema.
This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Macular Edema, Diabetic Retinopathy
7. Study Design
Study Phase
Phase 2, Phase 3
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Bevacizumab
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diabetes mellitus
Clinically significant macular edema
Possibility of performing macular OCT
Consent of patient for inclusion in the study
Exclusion Criteria:
History of macular photocoagulation in less than 6 months of inclusion in the study
Necessity of surgical intervention
Rejection of the remaining in the study by patient
12. IPD Sharing Statement
Learn more about this trial
Intravitreal Bevacizumab for Diabetic Macular Edema
We'll reach out to this number within 24 hrs